1. Introduction
===============

*Tupistra chinensis* Baker., a species in the *Tupistra* genus of the Liliaceae family, is used as an endemic herbal medicine, known as "Kai-Kou-Jian", in the Qinba Mountains of Shaanxi Province in China \[[@B1-molecules-20-13659]\]. The roots and rhizomes of *T.* c*hinensis* are commonly used as folk medicine to treat throat irritation, rheumatic diseases and snake-bites \[[@B2-molecules-20-13659],[@B3-molecules-20-13659]\]. Modern pharmacological experiments have showed that the extracts of this species possess significant antitumor activities \[[@B4-molecules-20-13659],[@B5-molecules-20-13659]\], moreover, two main kinds of components---cardenolides and saponins---were isolated from *T. chinensis* \[[@B3-molecules-20-13659],[@B6-molecules-20-13659],[@B7-molecules-20-13659]\]. As part of our research project to find more diverse bioactive leading compounds from the medicinal herbs of the Qinba Mountains \[[@B8-molecules-20-13659],[@B9-molecules-20-13659],[@B10-molecules-20-13659],[@B11-molecules-20-13659]\], the chemical constituents and pharmacological studies of *T. chinensis* were investigated, and two new furostanol saponins, 1β,2β,3β,4β,5β,26-hexahydroxyfurost-20(22),25(27)-dien-5,26-*O*-β-[d]{.smallcaps}-glucopyranoside (**1**), 1β,2β,3β,4β,5β,6β,7α,23ξ,26-nonahydroxyfurost-20(22),25(27)-dien-26-*O*-β-[d]{.smallcaps}-glucopyranoside (**2**), and a new spirostanol saponin (20*S*,22*R*)-spirost-25(27)-en-1β,3β,5β-trihydroxy-1-*O*-β-[d]{.smallcaps}-xyloside (**3**) were obtained from the roots and rhizomes of *T. chinensis* together with the two known compounds tupisteroide B (**4**) and 5β-furost-Δ^25(27)^-en-1β,2β,3β,4β,5β,7α,22ξ,26-octahydroxy-6-one-26-*O*-β-[d]{.smallcaps}-glucopyranoside (**5**) ([Figure 1](#molecules-20-13659-f001){ref-type="fig"}). The cytotoxic activity of **1**--**4** was evaluated on human A549 and H1299 tumor cells.

![Structures of compounds **1**--**5**.](molecules-20-13659-g001){#molecules-20-13659-f001}

2. Results and Discussion
=========================

Compound **1** was obtained as a white amorphous powder, which showed positive reactions in the Liebermann-Burchard, Ehrlich and Molisch reactions, suggesting that **1** was a furostanol glycoside. Its molecular formula was determined as C~39~H~62~O~17~ from the HR-ESI-MS peak at *m*/*z* 801.3855 \[M − H\]^−^. The ^1^H-NMR spectrum showed three methyl protons at δ~H~ 0.67 (3H, s), 1.70 (3H, s) and 1.58 (3H, s), two *exo*-methylene protons (δ~H~ 5.35 (1H, brs) and 5.04 (1H, brs)), as well as signals for two anomeric protons at (δ~H~ 5.28 (d, *J* = 7.8 Hz) and 4.89 (1H, d, *J* = 7.7 Hz)). The ^13^C-NMR spectrum displayed 39 carbon signals, 27 of which belonged to the aglycone carbons, while the remaining signals were assignable to two glucosyl moieties (δ~C~ 103.8, 75.8, 78.5, 71.7, 78.6 and 62.6, and δ~C~ 97.4, 76.2, 78.6, 71.9, 78.8 and 62.8). Among carbon signals of the aglycone, δ~C~ 146.2 and 111.6 were due to an olefinic bond group, δ~C~ 14.3, 13.7 and 11.7 were due to three methyl groups, and δ~C~ 77.8, 68.1, 75.2, 67.6, 87.4, 84.4, 64.5 and 71.7 were due to eight oxygenated carbon groups, which indicated that **1** was a furostanol saponin with multiple hydroxyl groups. The structure of **1** was finally determined by analysis of its 2D NMR data (see [Figure 2](#molecules-20-13659-f002){ref-type="fig"}). The HMQC experiment allowed for the assignments of the proton and protonated carbon resonances in the NMR spectra of **1**. HMQC correlations of (δ~H~ 5.35 (H-27a) and 5.04 (H-27b)) to δ~C~ 111.6, showed the appearance of a terminal olefinic bond at C-27. Then, HMBC correlations of H-27/C-24, C-25 and C-26, H-24/C-22, C-23, C-25 and C-26, H-26/C-24, C-25 and C-27, indicated that the appearance of an isopentene group, linked at C-22 of the tetrahydrofuran ring of the furostanol saponin. Moreover, HMBC correlations of H-19/C-1, C-5, C-9 and C-10, H-3/C-1, C-2 and C-5, and H-6/C-4 and C-5, indicated that all hydroxyl groups were linked at C-1--C-5 of the A ring of the furostanol saponin (see [Figure 2](#molecules-20-13659-f002){ref-type="fig"}). Furthermore, the remaining HMBC correlations of H-18/C-12, C-13, C-14 and C-17, H-16/C-13, C-17, C-20 and C-22, H-21/C-17, C-20 and C-22, were assigned (see [Figure 2](#molecules-20-13659-f002){ref-type="fig"}). Therefore, the aglycone of **1** was identified as 1, 2, 3, 4, 5, 26-hexanol-furost-20 (22),25(27)-dien. In addition, the HMBC correlation signals of H-Glc-1′/C-5 and H-Glc-1′′/C-26, indicated that glucosyl groups were connected as (Glc-1′′-*O*-C-26) and (Glc-1′-*O*-C-5) (see [Figure 2](#molecules-20-13659-f002){ref-type="fig"}). The two glucosyl moieties were identified as [d]{.smallcaps}-glucose by acid hydrolysis of **1**, followed by TLC comparison with a reference compound and optical rotation determination \[[@B12-molecules-20-13659]\], and judged to be in a β-configuration \[[@B13-molecules-20-13659]\] from the coupling constants of the anomeric protons (7.8 Hz and 7.7 Hz, respectively). In the NOESY spectrum of **1**, the NOE correlations of Me-19/H-8, H-9/H-4, H-4/H-3 and H-2, and H-2/H-1 were observed (see [Figure 2](#molecules-20-13659-f002){ref-type="fig"}), indicated α-axial configurations of H-1, H-2, H-3 and H-4, and β-orientation of Me-19, 1-OH, 2-OH, 3-OH, 4-OH and 5-OH, which supported the A/B *cis* ring junction pattern; the NOE correlations of Me-19/H-8, H-8/Me-18, and H-14/H-9, H-16 and H-17, supported the B/C and C/D *trans* ring junction pattern; and the NOE correlations of Me-18/H-15b, H-15a/H-16 and H-17, and H-17/Me-21, suggested an α-orientation of Me-21 (see [Figure 2](#molecules-20-13659-f002){ref-type="fig"}). Therefore, compound **1** was identified as 1β,2β,3β,4β,5β,26-hexahydroxyfurost-20(22),25(27)-dien-5,26-*O*-β-[d]{.smallcaps}-glucopyranoside.

![Key HMBC and NOESY correlations of the compound **1**.](molecules-20-13659-g002){#molecules-20-13659-f002}

Compound **2** was obtained as a white amorphous powder, which showed positive reactions in the Liebermann-Burchard, Ehrlich, and Molisch tests, suggesting that **2** was a furostanol glycoside. The molecular formula C~33~H~52~O~15~ was deduced from the HR-ESI-MS peak at *m*/*z* 711.3198 \[M + Na\]^+^. Comparison of the HR-ESI-MS and NMR data of **2** and **1**, indicated almost similar NMR spectroscopic features, except for the number of oxygenated methine groups. In the ^13^C-NMR spectrum of **2**, only one glucosyl moiety (δ~C~ 104.2, 75.6, 80.0, 72.1, 79.0, 63.2) was recognized, however, nine oxygenated carbon groups of the aglycone at δ~C~ 79.1, 67.7, 76.1, 70.2, 78.6, 74.0, 72.5, 64.8 and 72.7 were identified. Meanwhile, the spectroscopic features of **2** were similar to those of tupisteroide B (4), indicating that seven hydroxyl groups were linked at C-1--C-7 of the furostanol saponin, which was confirmed by the ^1^H-^1^H COSY correlation of H-1/H-2/H-3/H-4 and H-6/H-7 and the HMBC correlation of H-19/C-1, C-5, C-9 and C-10, and H-6/C-4 and C-5 (see [Figure 3](#molecules-20-13659-f003){ref-type="fig"}). The 26-OH was connected with the glucosyl moiety from the correlation signals of H-Glc-1′/C-26 in the HMBC spectra (see [Figure 3](#molecules-20-13659-f003){ref-type="fig"}). The remaining hydroxyl group was deduced to be linked at C-23, from one oxygen-bearing methine signal occurring at δ~C~ 64.8 in **2**, instead of a methylene carbon (C-23) at δ~C~ 34.3 in **4**, which was correlated with a proton signal at δ~H~ 5.13 (dd, *J* = 6.0, 8.0 Hz, H-23) in the HMQC spectrum, and the correlation signals of H-23/H-24 in the ^1^H-^1^H COSY spectrum, the correlation signals of H-23/C-20, C-22, C-24 and C-25, H-24/C-22, C-23, C-25, C-26 and C-27, and H-27/C-24, C-25 and C-26 in the HMBC spectrum (see [Figure 3](#molecules-20-13659-f003){ref-type="fig"}). In addition, the glucosyl moiety was identified as β-[d]{.smallcaps}-glucose by the acid hydrolysis procedure and the coupling constant analysis of the anomeric proton (*J* = 7.8 Hz), according to the same protocol as that described for **1**. Thus, the planar structure of **2** was deduced as 1,2,3,4,5,6,7,23,26-nonanolfurost-20(22),25(27)-dien-26-*O*-β-[d]{.smallcaps}-glucose. In the NOESY spectrum of **2**, the NOE correlations of Me-19/H-8, H-4/H-2, H-3 and H-9, and H-2/H-1 were observed, indicating α-axial configurations of H-1, H-2, H-3, and H-4, and β-orientation of Me-19, 1-OH, 2-OH, 3-OH, 4-OH and 5-OH, which supported the A/B *cis* ring junction pattern (see [Figure 3](#molecules-20-13659-f003){ref-type="fig"}). Besides, NOE correlation of H-7/H-8 was observed and no correlation signals was occurred between Me-19/H-6, which indicated α-axial configuration of 7-OH and β-orientation of 6-OH (see [Figure 3](#molecules-20-13659-f003){ref-type="fig"}). Finally, the NOE correlations of H-8/Me-19 and Me-18, and H-14/H-16 and H-17, supported the B/C and C/D *trans* ring junction pattern; and the NOE correlations of Me-18/H-15b, H-15a/H-16 and H-17, and H-17/Me-21, suggested the α-orientation of Me-21 (see [Figure 3](#molecules-20-13659-f003){ref-type="fig"}). Therefore, compound **2** was identified as 1β,2β,3β,4β,5β,6β,7α,23ξ,26-nonahydroxyfurost-20(22),25(27)-dien-26-*O*-β-[d]{.smallcaps}-glucopyranoside.

![Key HMBC, ^1^H-^1^H COSY and NOESY correlations of the compound **2**.](molecules-20-13659-g003){#molecules-20-13659-f003}

Compound **3** was obtained as a white amorphous powder, and the molecular formula of C~32~H~50~O~9~ was established by the HR-ESI-MS signal at *m*/*z* 579.3590 \[M + H\]^+^. The ^13^C-NMR spectrum exhibited 32 carbon signals, 27 of which were attributed to the aglycone carbons, while the remaining signals were assignable to a characteristic of a xylosyl moiety (δ~C~ 104.1, 75.8, 78.9, 71.5 and 68.1), which was identified as β-[d]{.smallcaps}-xylose by the coupling constant analysis of the anomeric proton (*J* = 7.2 Hz), the acid hydrolysis procedure, TLC comparison, and the optical rotation determination. Among the aglycone carbon signals, the quaternary carbon signal at δ~C~ 109.9 (see, [Table 1](#molecules-20-13659-t001){ref-type="table"}), was identified as an acetal carbon (C-22), a characteristic signal of spirostanol or norspirostanol saponin \[[@B14-molecules-20-13659]\]. In HMBC spectrum, the anomeric proton \[4.81 (1H, d, *J* = 7.2 Hz)\] of the xylose was correlated with δ~C~ 82.5, which was confirmed as C-1 for the HMQC correlation of δ~H~ 4.26 (H-1)/δ~C~ 82.5 (C-1), ^1^H-^1^H COSY correlations of H-1/H-2/H-3/H-4, and HMBC correlations of H-19/C-1, C-5, C-9 and C-10 (see, [Figure 4](#molecules-20-13659-f004){ref-type="fig"}). Moreover, HMBC correlations of H-18/C-12, C-13, C-14 and C-17, H-21/C-17, C-20 and C-22, H-23/C-22, and H-27/C-24, C-25 and C-26, were observed (see, [Figure 4](#molecules-20-13659-f004){ref-type="fig"}).The above data indicated the planar structure of **3** as spirost-25(27)-en-1,3,5-trihydroxy-1-*O*-β-[d]{.smallcaps}-xyloside. In the NOESY spectrum of **3** (see, [Figure 4](#molecules-20-13659-f004){ref-type="fig"}), the NOE correlations of Me-19/H-8, H-3/H-2a and H-4, H-2a/H-1, and H-4a/H-7a and H-9, indicated α-axial configurations of H-1 and H-3, and β-orientation of Me-19, 1-OH, 3-OH and 5-OH, which supported the A/B *cis* ring junction pattern; the NOE correlations of H-8/Me-19 and Me-18, and H-14/H-9 and H-7a, supported the B/C and C/D *trans* ring junction pattern; the NOE correlations of Me-18/H-15b and H-20, H-15a/H-16 and H-17, and H-17/Me-21, suggested α-orientation of Me-21. These spectra data was almost similar to those of (20*S*,22*R*)-*1*β,3β,5β-trihydroxyspirost-25(27)-en-5-*O*-β-[d]{.smallcaps}-glucopyranoside \[[@B8-molecules-20-13659]\], expect for the site of glycosylation. Therefore, compound **3** was elucidated as (20*S*, 22*R*)-spirost-25(27)-en-1β,3β,5β-trihydroxy-1-*O*-β-[d]{.smallcaps}-xyloside.

molecules-20-13659-t001_Table 1

###### 

^1^H-NMR and ^13^C-NMR spectral data of compounds **1**--**3**.

  Position   1       2                                         3                                                                          
  ---------- ------- ----------------------------------------- ------- ---------------------------------------------------------- ------- -----------------------------------------
  1          77.8    4.25 (brs)                                79.1    4.29 (brs)                                                 82.5    4.26 (brs)
  2          68.1    4.38 (brs)                                67.7    4.33 (brs)                                                 30.4    2.53 (H-2a, *ca*.) 1.85 (H-2b, *ca*.)
  3          75.2    4.70 (brs)                                76.1    4.77 (brs)                                                 67.8    4.59 (brs)
  4          67.6    4.08 (brs)                                70.2    5.33 (brs)                                                 40.0    2.40 (H-4a, *ca*.) 2.04 (H-4b, *ca*.)
  5          87.4    \-                                        78.6    \-                                                         74.7    \-
  6          24.9    1.93 (*ca*.), 2.80 (*ca*.)                74.0    5.03 (brs)                                                 36.3    1.54 (*ca*.), 1.90 (*ca*.)
  7          28.5    1.1 (*ca*.), 1.51 (*ca*.)                 72.5    4.49 (brs)                                                 29.2    0.98 (H-7a, *ca*.) 1.51 (H-7b, *ca*.)
  8          34.4    1.59 (*ca*.)                              34.8    2.62 (*ca*.)                                               35.4    1.67 (*ca*.)
  9          46.6    1.19 (*ca*.)                              37.8    2.05 (*ca*.)                                               46.3    1.15 (*ca*.)
  10         46.2    \-                                        46.3    \-                                                         44.9    \-
  11         21.9    1.41 (*ca*.), 1.44 (*ca*.)                21.9    1.61 (*ca*.), 1.67 (*ca*.)                                 22.3    1.14(*ca*.),1.38 (*ca*.)
  12         39.7    1.62 (d, 12.0), 1.15 (*ca*.)              40.0    1.70 (d, 12.0), 1.24 (*ca*.)                               40.5    1.73 (d, 12.5), 1.13 (*ca*.)
  13         43.3    \-                                        43.8    \-                                                         41.2    \-
  14         54.3    0.76 (*ca*.)                              48.9    1.96 (*ca*.)                                               56.7    1.12 (*ca*.)
  15         31.0    2.48 (H-15a, *ca*.) 2.38 (H-15b, *ca*.)   34.7    2.58 (H-15a, *ca*.) 1.65 (H-15b, *ca*.)                    32.7    2.07 (H-15a, *ca*.) 1.48 (H-15b, *ca*.)
  16         84.4    4.77 (q, 7.5)                             85.1    4.87 (*ca*.)                                               81.9    4.62 (q, 7.2)
  17         64.5    2.42 (*ca*.)                              65.3    2.57 (*ca*.)                                               63.5    1.88 (*ca*.)
  18         14.3    0.67 (s)                                  14.6    0.81 (s)                                                   17.0    0.87 (s)
  19         13.7    1.70 (s)                                  16.0    1.99 (s)                                                   14.4    1.59 (s)
  20         103.9   \-                                        105.9   \-                                                         42.4    2.00(*ca*.)
  21         11.7    1.58 (s)                                  12.1    1.74 (s)                                                   15.5    1.10 (d, 8.0)
  22         151.8   \-                                        154.2   \-                                                         109.9   \-
  23         34.3    1.45 (*ca*.), 2.04 (*ca*.)                64.8    5.13 (dd, 6.0, 8.0)                                        33.7    1.81 (*ca*.)
  24         24.6    2.37 (*ca.*), 2.47 (*ca.*)                40.3    2.88 (H-24a, dd, 6.0, 14.3), 3.10 (H-24b, dd, 8.0, 14.3)   29.4    2.26 (*ca*.) 2.74 (*ca*.)
  25         146.2   \-                                        144.4   \-                                                         144.9   \-
  26         71.7    4.58 (d, 13.0) 4.34 (d, 13.0)             72.7    4.75 (d, 13.0) 4.61 (d, 13.0)                              65.5    4.50 (d, 12.1) 4.07 (d, 12.1)
  27         111.6   5.35 (H-27a, s) 5.04 (H-27b, s)           114.6   5.47 (H-27a, s) 5.28 (H-27b, s)                            109.2   4.81(H-27a, s) 4.84 (H-27b, s)
  1*\'*      97.4    5.28 (d, 7.8)                             104.2   5.0 (d, 7.8)                                               104.1   4.81 (d, 7.2)
  2*\'*      76.2    3.95 (*ca*.)                              75.6    4.12 (*ca*.)                                               75.8    3.99 (*ca*.)
  3*\'*      78.6    4.01 (*ca*.)                              80.0    4.36 (*ca*.)                                               78.9    4.21 (*ca*.)
  4*\'*      71.9    4.02 (*ca*.)                              72.1    4.27 (*ca*.)                                               71.5    4.23 (*ca*.)
  5*\'*      78.8    4.22 (*ca*.)                              79.0    3.96 (*ca*.)                                               68.1    3.78 (t, 10.5), 4.42 (dd, 4.5, 11.5)
  6*\'*      62.8    4.52 (*ca*.), 4.21 (*ca*.)                63.2    4.58 (dd, 2.0, 11.8), 4.41 (dd, 5.5, 11.8)                 \-      \-
  1*\'\'*    103.8   4.89 (d, 7.7)                             \-      \-                                                         \-      \-
  2*\'\'*    75.8    4.03 (*ca*.)                              \-      \-                                                         \-      \-
  3*\'\'*    78.5    4.22 (*ca*.)                              \-      \-                                                         \-      \-
  4*\'\'*    71.7    4.19 (*ca*.)                              \-      \-                                                         \-      \-
  5*\'\'*    78.6    3.92 (*ca*.)                              \-      \-                                                         \-      \-
  6*\'\'*    62.6    4.52 (*ca.*), 4.35 (*ca.*)                \-      \-                                                         \-      \-

^a^ δ in pyridine-*d*~5~, in ppm from TMS; coupling constants (*J*) in Hz; ^1^H-NMR at 500 MHz and ^13^C-NMR at 125 MHz; ^b^ δ in pyridine-*d*~5~, ^1^H-NMR at 600 MHz and ^13^C-NMR at 150 MHz; ^c^ δ in pyridine-*d*~5~, ^1^H-NMR at 400 MHz and ^13^C-NMR at 100 MHz.

![Key HMBC, ^1^H-^1^H COSY and NOESY correlations of the compound **3**.](molecules-20-13659-g004){#molecules-20-13659-f004}

Additionally, the known furostanol saponins were identified by comparison of their spectroscopic data with those reported in the literature as tupisteroide B (**4**) \[[@B15-molecules-20-13659]\] and 5β-furost-Δ^25(27)^-en-1β,2β,3β,4β,5β,7α,22ξ,26-octaol-6-one-26-*O*-β-[d]{.smallcaps}-glucopyranoside (**5**) \[[@B16-molecules-20-13659]\].

The cytotoxic activity of **1**--**4** towards the A549 and H1299 tumor cell lines was measured by the MTT method. Compound **3** exhibited cytotoxicity against A549 cells (IC~50~ 86.63 ± 2.33 μmol·L^−1^) and H1299 cells (IC~50~ 88.21 ± 1.34 μmol·L^−1^, see [Table 2](#molecules-20-13659-t002){ref-type="table"} and [Table 3](#molecules-20-13659-t003){ref-type="table"}). Considering **3** is a spirostanol saponin, our results showed the cytotoxic activity of this type of steroidal saponin as mentioned in the literature \[[@B8-molecules-20-13659],[@B17-molecules-20-13659],[@B18-molecules-20-13659],[@B19-molecules-20-13659]\].

molecules-20-13659-t002_Table 2

###### 

Activities of compounds **1**--**4** on proliferation of the H1299 cells.

  Comp.   1 μM               3 μM                10 μM               30 μM               100 μM              IC~50~ μM
  ------- ------------------ ------------------- ------------------- ------------------- ------------------- --------------
  1       1.93 ± 0.95 \*\*   13.50 ± 1.81 \*\*   14.69 ± 1.41 \*\*   16.53 ± 1.26 \*\*   16.90 ± 0.69 \*\*   \>100
  2       3.95 ± 2.09 \*\*   5.75 ± 1.48 \*\*    11.50 ± 3.22 \*\*   16.17 ± 1.50 \*\*   20.04 ± 1.36 \*\*   \>100
  3       4.55 ± 1.10 \*\*   8.04 ± 1.94 \*\*    13.47 ± 0.61 \*\*   17.39 ± 0.73 \*\*   55.74 ± 0.87 \*\*   88.21 ± 1.34
  4       4.01 ± 0.86 \*\*   9.26 ± 0.44 \*\*    11.46 ± 2.91 \*\*   13.47 ± 1.49 \*\*   26.07 ± 0.99 \*\*   \>100
  5-FU    3.07 ± 0.52        5.21 ± 0.28         17.39 ± 1.11        47.88 ± 1.38        71.96 ± 2.49        38.65 ± 1.59

The data are expressed as mean ± SD of three independent experiments (\*\* *p* \< 0.01 *vs.* control).

molecules-20-13659-t003_Table 3

###### 

Activities of compounds **1**--**4** on proliferation of the A549 cells.

  Comp.   1 μM               3 μM                10 μM               30 μM               100 μM              IC~50~ μM
  ------- ------------------ ------------------- ------------------- ------------------- ------------------- --------------
  1       3.75 ± 1.24 \*\*   11.62 ± 1.88 \*\*   12.83 ± 2.02 \*\*   14.35 ± 0.77 \*\*   20.19 ± 3.63 \*\*   \>100
  2       4.17 ± 1.30 \*\*   7.68 ± 1.27 \*\*    11.07 ± 1.57 \*\*   13.80 ± 2.05 \*\*   23.11 ± 0.74 \*\*   \>100
  3       3.95 ± 0.95 \*\*   7.90 ± 1.67 \*\*    13.05 ± 1.75 \*\*   20.60 ± 2.40 \*\*   56.17 ± 1.98 \*\*   86.63 ± 2.33
  4       2.93 ± 1.18 \*\*   6.65 ± 0.94 \*\*    7.01 ± 2.47 \*\*    13.21 ± 1.40 \*\*   24.75 ± 1.62 \*\*   \>100
  5-FU    6.97 ± 0.82        9.03 ± 1.21         23.76 ± 1.22        42.18 ± 1.22        69.24 ± 2.05        42.78 ± 1.63

The data are expressed as mean ± SD of three independent experiments (\*\* *p* \< 0.01 *vs.* control).

3. Experimental Section
=======================

3.1. General Information
------------------------

The IR spectra were recorded on a TENSOR-27 instrument (Bruker, Rheinstetten, Germany). ESI-MS was performed on a Quattro Premier instrument (Waters, Milford, MA, USA). The HR-ESI-MS spectra were recorded on an Agilent Technologies 6550 Q-TOF (Santa Clara, CA, USA). 1D and 2D NMR spectra were recorded on Bruker-AVANCE 400, Bruker-AVANCE 500 and Bruker-AVANCE 600 instrument (Bruker, Rheinstetten, Germany) with TMS as an internal standard. The analytical HPLC was performed on a Waters 2695 Separations Module coupled with a 2996 Photodiode Array Detector and a Accurasil C18 column (4.6 mm × 250 mm, 5 mm particles, Ameritech, Chicago, IL, USA). Semipreparative HPLC was performed on a system comprising an LC-6AD pump (Shimadzu, Kyoto, Japan) equipped with a SPD-20A UV detector and a Ultimate XB-C18 (10 mm × 250 mm, 5 mm particles) or YMC-Pack-ODS-A (10 mm × 250 mm, 5 mm particles). D101 was from Sunresin New Materials Co. Ltd. (Xi'an, China). Silica gel was purchased from Qingdao Haiyang Chemical Group Corporation (Qingdao, China).

3.2. Plant Material
-------------------

The roots and rhizomes of *T. chinensis* Baker were collected from the Taibai region of Qinba Mountains in Shaanxi Province, China, in August 2010, and identified by senior experimentalist Jitao Wang. A voucher specimen (herbarium No. 20100816) has been deposited in the Medicinal Plants Herbarium (MPH), Shaanxi University of Chinese Medicine, Xianyang, China.

3.3. Extraction and Isolation
-----------------------------

The air-dried and powdered underground parts of *T. chinensis* (1.5 kg) were extracted with 65% EtOH (15 L) three times at 80 °C. The combined EtOH extracts were evaporated to 6 L, and applied to a resin D101 column, eluting with H~2~O, 20% EtOH, 60% EtOH, and 95% EtOH to give four fractions (Fr.1--Fr.4). Fr.3 (75 g) was subjected to column chromatography (CC) on silica gel, eluting with gradient solvent system (CHCl~3~--MeOH--H~2~O, 100:0:0--0:50:50) to yield nine fractions (Fr.3-1--Fr.3-9). Fr.3-6 (5 g) was separated over silica gel using CHCl~3~--MeOH (100:1--50:50) as eluent to obtain eight fractions (Fr.3-6-1--Fr.3-6-8). Fr.3-6-5 (150 mg) and Fr.3-6-7 (370 mg) were purified by HPLC (YMC-Pack-ODS-A, 10 mm × 250 mm, 5 μm particles, flow rate: 1.0 mL∙min^−1^) with CH~3~OH--H~2~O (45:55) as mobile phase to afford **1** (23 mg; *t~R~* = 35 min), **2** (15 mg; *t~R~* = 27 min), **3** (20 mg; *t~R~* = 43 min), **4** (27 mg; *t~R~* = 47 min) and **5** (1.8 mg; *t~R~* = 65 min).

3.4. 1β,2β,3β,4β,5β,26-Hexahydroxyfurost-20(22),25(27)-dien-5,26-O-β-[d]{.smallcaps}-glucopyranoside (**1**)
------------------------------------------------------------------------------------------------------------

A white amorphous powder, IR (KBr) ν~max~: 3450, 2980, 1694, 1025, 907, 804, 772 cm^−1^. ^1^H-NMR (500 MHz, pyridine-*d*~5~) and ^13^C-NMR (125 MHz, pyridine-*d*~5~) spectral data, see [Table 1](#molecules-20-13659-t001){ref-type="table"}; *m*/*z* 801.3855 \[M − H\]^−^ (calcd. for C~39~H~61~O~17~, 801.3909).

3.5. 1β,2β,3β,4β,5β,6β,7α,23ξ,26-Nonahydroxyfurost-20(22),25(27)-dien-26-O-β-[d]{.smallcaps}-glucopyranoside (**2**)
--------------------------------------------------------------------------------------------------------------------

A white amorphous powder, IR (KBr) ν~max~: 3475, 2980, 1742, 1062, 904, 804 cm^−1^. ^1^H-NMR (600 MHz, pyridine-*d*~5~) and ^13^C-NMR (150 MHz, pyridine-*d*~5~) spectral data, see [Table 1](#molecules-20-13659-t001){ref-type="table"}; *m*/*z* 711.3198 \[M + Na\]^+^ (calcd. for C~33~H~52~O~15~Na, 711.3204).

3.6. (20S,22R)-Spirost-25(27)-en-1β,3β,5β-trihydroxy-1-O-β-[d]{.smallcaps}-xyloside (**3**)
-------------------------------------------------------------------------------------------

A white amorphous powder; IR (KBr) ν~max~: 3306, 2922, 1650, 1042, 989, 917, 892, 876 cm^−1^; ^1^H-NMR (400 MHz, pyridine-*d*~5~) and ^13^C-NMR (100 MHz, pyridine-*d*~5~) spectral data, see [Table 1](#molecules-20-13659-t001){ref-type="table"}; *m*/*z* 579.3590 \[M + H\]^+^ (calcd. for C~32~H~51~O~9~, 579.3633).

3.7. Acid Hydrolysis of Compounds **1**, **2**, **3** and Absolute Sugar Configuration Determination
----------------------------------------------------------------------------------------------------

The solutions of compounds **1** (3 mg), **2** (3 mg) and **3** (5 mg) were hydrolyzed with 2*N* HCl (5 mL) for 5 h at 80 °C, respectively. The reaction mixtures were concentrated and dried by N~2~, and then water (5 mL) was added and the mixtures were extracted with EtOAc (3 × 5 mL). The aqueous layers of **1** and **2** were subjected to CC over silica gel eluted with MeCN--H~2~O (8:1) to yield [d]{.smallcaps}-glucose, which was determined by TLC comparison (MeCN--H~2~O, 6:1) with the authentic sugar and the optical rotation determination $\left\lbrack \alpha \right\rbrack_{D}^{20}$ +49.2 (*c* 0.16, H~2~O). The aqueous layer of **3** was subjected to CC over silica gel eluted with MeCN--H~2~O (8:1--15:1) to yield [d]{.smallcaps}-xylose, which was identified by TLC comparison with the authentic sugar and the optical rotation determination $\left\lbrack \alpha \right\rbrack_{D}^{20}$ +17.9 (*c* 0.14, H~2~O).

3.8. Cytotoxicity Assay
-----------------------

The cytotoxic activity assays towards the A549 and H1299 tumor cell lines were measured by the MTT method *in vitro*, using 5-fluorouracil as positive control. Briefly, 1 × 10^4^ mL^−1^ cells were seeded into 96-well plates and allowed to adhere for 24 h. Compounds **1**--**4** were dissolved in DMSO and diluted with complete medium to five concentration levels (from 0.001 mmol·L^−1^ to 0.1 mmol·L^−1^) for inhibition rate determination. After incubation at 37 °C for 4 h, the supernatant was removed before adding DMSO (100 μL) to each well. 5-Fluorouracil (5-Fu) was used as positive control. The inhibition rate (IR) and IC~50~ were calculated. Values are mean ± SD, *n* = 3, \*\* *p* \< 0.01 *vs.* DMEM control. Compound **3** exhibited cytotoxicity against A549 cells (IC~50~ 86.63 ± 2.33 μmol·L^−1^) and H1299 cells (IC~50~ 88.21 ± 1.34 μmol·L^−1^), while the positive control of 5-Fu exhibited cytotoxicity against A549 cells (IC~50~ 42.78 ± 1.63 μmol·L^−1^) and H1299 cells (IC~50~ 38.65 ± 1.59 μmol·L^−1^), respectively, (see [Table 2](#molecules-20-13659-t002){ref-type="table"} and [Table 3](#molecules-20-13659-t003){ref-type="table"}).
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###### 

Click here for additional data file.

IR, HR-ESI-MS, ^1^H-NMR ^13^C-NMR and 2D NMR spectra for compounds **1**--**3** can be accessed at: <http://www.mdpi.com/1420-3049/20/08/13659/s1>.
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